title: In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin.
abstract: Vapreotide, a long-acting somatostatin analog, possesses an analgesic effect. The purpose of this work was to determine a tachykinergic involvement. Vapreotide reduced substance P-induced biting and scratching in mice. This inhibitory effect of substance P action was confirmed by experiments performed on the bronchial apparatus of guinea-pigs known to possess tachykinin NK1 and NK2 receptors. (i) Vapreotide reduced the substance P-induced plasmatic exudation. (ii) It inhibited selectively the tachykinin-dependent second contractile phase induced by electrical field stimulation of isolated bronchi. (iii) It shifted to the right the concentration-effect curve of substance P-induced contraction of isolated main bronchi. The peptide displaced [3H]substance P (IC50 = 3.3 +/- 1.8 x 10(-7) M) from guinea-pig bronchial tachykinin NK1 sites. The displacement of [125I]neurokinin A, a specific tachykinin NK2 receptor ligand, needed higher concentrations (IC50 = 4.5 +/- 0.6 x 10(-6) M). It is concluded that vapreotide possesses an antagonist activity on guinea-pig tachykinin NK1 receptors; the involvement in its analgesic action is discussed.
authors.affiliation: Laboratoire de Pharmacologie Médicale, Equipe NPPUA, Faculté de Médecine, Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Bétoin
authors.forename: C
authors.initials: C
authors.lastname: Advenier
authors.forename: V
authors.initials: V
authors.lastname: Fardin
authors.forename: G
authors.initials: G
authors.lastname: Wilcox
authors.forename: J
authors.initials: J
authors.lastname: Lavarenne
authors.forename: A
authors.initials: A
authors.lastname: Eschalier
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000700:Analgesics / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D001980:Bronchi / Q000187:drug effects / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism; D004558:Electric Stimulation; D005260:Female; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D015288:Neurokinin A / Q000031:analogs & derivatives / Q000494:pharmacology; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D013373:Substance P / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000700:Analgesics; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments; D018040:Receptors, Neurokinin-1; C061060:neurokinin A (4-10), Nle(10)-; C051458:vapreotide; D013373:Substance P; D013004:Somatostatin; D015288:Neurokinin A; D000109:Acetylcholine